The direct answer

A credible myostatin claim should identify the exact intervention, the studied population, the comparator, the measured outcome, and the follow-up period. These details let you check whether the source supports the claim being made.

Start with the original record

Find the actual paper, official label, or trial record. A list of references is only a starting point: the linked material must support the sentence beside it. Check the publication date and whether a correction or newer label changes the interpretation.

A dated FDA label is especially useful for an approved medicine. For example, the September 2026 Isembyld label contains risk information that should be retained when discussing apitegromab.[1]

Match five parts of the claim

Write the claim as a sentence with five slots: “This intervention, in these participants, compared with this alternative, changed this outcome, over this period.” Missing slots are missing context.

  • Identity: was the actual formulation tested?
  • Population: animals, healthy volunteers, or people with a named disease?
  • Comparator: placebo, another treatment, or only a before-and-after observation?
  • Outcome: tissue measurement, strength test, symptom, or daily function?
  • Time: an acute observation or a sustained result?

Look for the result that was planned

Identify the study’s primary endpoint and analysis population before focusing on a favorable subgroup. A study can report several interesting observations while its principal question remains unanswered.

For example, an earlier MYO-029 trial did not demonstrate improved exploratory strength or function outcomes, and was not powered to establish efficacy.[2] That is more informative than a broad statement that “a myostatin antibody was tested in humans.”

Read uncertainty alongside benefit

Check the sample size, missing data, confidence interval where provided, adverse events, and stopping decisions. These details affect how far a finding can be generalized. An absence of a detected problem in a small study is not proof that the problem cannot occur.

Avoid claims that a certificate of analysis or research-use label replaces clinical evidence. FDA’s 2024 Summit Research Peptides letter illustrates that a research-use disclaimer did not determine intended use when human-treatment marketing was present.[3] The letter concerned named GLP-1-related products, not a clinical verdict on every peptide.

Keep an evidence note

Record the source URL, the exact result you are using, and the most important limitation. This small habit makes comparisons more reliable and makes future corrections easier.

The related interactive claim checklist is a simple way to identify missing details. It does not assign treatment suitability or predict a health outcome.

Questions, answered.

Does publication in a journal prove a product works?

No. You still need to inspect the design, population, intervention, and result. Publication and clinical applicability are different questions.

Can an uncontrolled study be useful?

Yes, as exploratory evidence. Without an appropriate comparison, however, it is harder to determine why an outcome changed.

Sources & further reading

Primary research and official records used for this page. Study results apply to the populations and interventions described.

  1. Isembyld (apitegromab-mstn) prescribing informationFDA-hosted prescribing information · Revised September 2026 · PDF
  2. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophyWagner et al. · Annals of Neurology · 2008 · Randomized trial
  3. Summit Research Peptides — FDA warning letter 695607U.S. Food and Drug Administration · December 10, 2024 · Named GLP-1-related products
Educational information, not individualized medical advice. This article has not been independently reviewed by a clinician. Regulatory and research details are dated; check the linked primary records for subsequent changes.